STOCKS TELEGRAPH

Tag: NASDAQ:ICU

  • Extended Session Boost For SeaStar (ICU) Amid Clinical Trial Advances

    Extended Session Boost For SeaStar (ICU) Amid Clinical Trial Advances

    SeaStar Medical Holding Corporation (NASDAQ: ICU) announced significant advancements in its pivotal trial. The news sparked a 13.50% rise in ICU stock, sending its price to $2.69 during after-market trading on Tuesday.

    New Site Activation and Enrollment Milestone

    SeaStar Medical (ICU) has activated Sentara Norfolk General Hospital in Norfolk, Virginia, marking the thirteenth active site in its ongoing trial. Nine severely sick adult patients were joined in November alone, increasing the total number of participants to 65. The NEUTRALIZE-AKI research aims to evaluate the safety and efficacy of the company’s proprietary Selective Cytopheretic Device (SCD) in 200 adult patients requiring continuous renal replacement therapy (CRRT) in critical care units.

    The study’s momentum has accelerated with twice of the patient enrollments in the first two months Q4 than those in the first three quarters of 2024. With plans to activate additional sites in December, SeaStar Medical is poised to meet its enrollment goals ahead of schedule.

    SCD’s Potential to Transform AKI Treatment

    Pilot trials have revealed that the SCD can save lives and lessen dialysis dependency in patients who are in severe condition. These results demonstrate the device’s potential to lessen the strain on healthcare systems while simultaneously improving patient outcomes.

    About 210,000 patients in the United States are estimated by SeaStar Medical to be addressable AKIs per year, which translates to a $1 billion peak sales potential for the SCD. Beyond AKI, the company plans to expand its focus to other hyperinflammatory conditions, including cardiorenal syndrome.

    Regulatory and Financial Support

    The U.S. Food and Drug Administration previously awarded the SCD Breakthrough Device Designation, highlighting its potential to treat life-threatening illnesses with significant advancements over existing treatments. In July 2024, the Centers for Medicare & Medicaid Services granted Category B coverage for certain expenses related to the NEUTRALIZE-AKI trial, further supporting the study’s financial viability and its critical role in advancing healthcare solutions.

  • SeaStar Medical (ICU) Stock Rises After-Hours Following A Key Presentation

    SeaStar Medical (ICU) Stock Rises After-Hours Following A Key Presentation

    The extended trading session last Friday showed a notable 7.33% increase in SeaStar Medical Holding Corporation (NASDAQ: ICU) shares, which ended the day at $3.57. This spike came after the company’s novel Selective Cytopheretic Device (SCD) pediatric therapeutic device, QUELIMMUNE, was presented at a major nephrology convention with encouraging new results.

    Presentation at 2024 Kidney Week

    Last week, during the American Society of Nephrology’s (ASN) Kidney Week 2024 in San Diego, SeaStar Medical (ICU) made a significant announcement. Data demonstrating QUELIMMUNE’s cost-saving potential in treating critically sick pediatric patients with acute kidney damage (AKI) linked to sepsis was initially provided by the firm. According to this ground-breaking research, healthcare organizations that use QUELIMMUNE as part of their treatment arsenal stand to gain significantly financially.

    QUELIMMUNE: Cost Savings and Clinical Benefits

    The analysis, titled “Cost Impact of An Immunomodulatory Selective Cytopheretic Device in Pediatrics (SCD-PED) in AKI due to Sepsis (AKI-S)”, revealed substantial cost reductions when using QUELIMMUNE. According to data from the Kids’ Inpatient Database (KID), the average cost of hospitalization for pediatric patients with AKI requiring continuous renal replacement therapy (CRRT) was $461,736 per hospitalization.

    The findings showed that treatment with QUELIMMUNE resulted in projected savings of approximately $30,000 per hospitalization. These savings were primarily driven by lower mortality rates and shorter hospital stays, underscoring the device’s clinical and operational efficiency.

    Broader Implications for Hospitals

    Importantly, these results indicate a strong potential for widespread adoption of QUELIMMUNE across hospital systems, particularly in managing pediatric AKI linked to sepsis. The Centers for Medicare & Medicaid Services (CMS) has already recognized the critical nature of sepsis through the SEP-1 protocol, further emphasizing the importance of innovative solutions like QUELIMMUNE in improving outcomes and reducing costs.

    SeaStar Medical’s Strong Presence at Kidney Week

    SeaStar Medical (ICU) continues to build its reputation at Kidney Week 2024 with the presentation of four posters. In addition to the QUELIMMUNE cost analysis, another poster presented by the company focuses on the reduction of hyperinflammatory markers in patients with AKI, highlighting further potential therapeutic benefits of its products.

  • SeaStar Medical (ICU) Stock Rising Before Hours

    SeaStar Medical (ICU) Stock Rising Before Hours

    SeaStar Medical Holding Corporation (NASDAQ: ICU) is experiencing a notable ascent in its market performance as dawn approaches. The shares of SeaStar Medical are currently exhibiting a remarkable surge, standing at 33.59% with a value of $1.03 during the pre-market trading session at last check. This remarkable upturn in the valuation of ICU shares can be attributed to a recently obtained regulatory approval for its product.

    SeaStar Medical (ICU) has achieved the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking Selective Cytopheretic Device (SCD), a cell-directed innovation tailored for use in hospital intensive care units (ICUs) treating acute kidney injury (AKI) and acute on chronic liver failure.

    This marks the third such accolade bestowed upon SeaStar Medical for the SCD device, promising a swifter journey through clinical development and regulatory review, focusing on the specific requirements of this patient group.

    Hepatorenal syndrome, a grave condition characterized by abrupt kidney function deterioration often linked to advanced liver cirrhosis, carries a high mortality rate. SeaStar’s SCD has demonstrated potential in enabling kidney recovery, opening doors for life-saving liver transplants. A pivotal investigator-led study at the University of Michigan explored the effects of SCD treatment on two patients afflicted with type 1 hepatorenal syndrome.

    Encouragingly, both cases exhibited favorable clinical outcomes. The first patient, struggling with hepatorenal syndrome resulting from acute alcoholic hepatitis, survived 90 days post a week of SCD treatment and underwent evaluation for liver transplantation. The second patient, facing hepatorenal syndrome due to non-alcoholic steatohepatitis (NASH), successfully received a liver transplant six days after concluding SCD therapy.

    These findings suggest that SCD’s immunomodulatory capabilities could play a crucial role in managing acute on chronic liver failure, offering a path toward liver transplantation. These noteworthy cases have been published in the prestigious American Society for Artificial Internal Organs Journal. This recognition underscores ICU’s potentially life-saving approach of addressing dysregulated immune responses.

    Furthermore, SCD has displayed promise in enhancing the performance of vital organs across a range of preclinical and clinical studies, spanning conditions such as sepsis, AKI, cardiorenal syndrome, and even COVID-19 management. ICU foresees that the ongoing pilot study at the University of Michigan will yield valuable insights for the design and execution of a pivotal study within this particular medical context.